REKIPLA Trademark

Trademark Overview

On Friday, September 9, 2016, a trademark application was filed for REKIPLA with the United States Patent and Trademark Office. The USPTO has given the REKIPLA trademark a serial number of 79196954. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, April 12, 2024. This trademark is owned by DAIICHI SANKYO COMPANY, LIMITED. The REKIPLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, stroke, dyslipidemia, thrombosis, hyperphosphatemia, diabetes, cancer, oncological disease, leukemia, metastasis, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, osteoporosis, age-related macular degeneration, kidney disease for human use, * excluding pharmaceutical preparations for the treatment and prevention of HIV *
rekipla

General Information

Serial Number79196954
Word MarkREKIPLA
Filing DateFriday, September 9, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, April 12, 2024
Registration Number5293481
Registration DateTuesday, September 26, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2017

Trademark Statements

Amendment to a Registration/Renewal CertificateThe drawing is amended to appear as follows: PUBLISH CUT, And, the standard character claim is inserted.
Certificate of Correction for RegistrationIn the statement, line 9, after "use", "excluding pharmaceutical preparations for the treatment and prevention of HIV." should be inserted.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of cardiovascular disease, stroke, dyslipidemia, thrombosis, hyperphosphatemia, diabetes, cancer, oncological disease, leukemia, metastasis, bacterial infection, viral infection, pain, central nervous system disease, neurological disease, mood disorders, musculoskeletal disorders, osteoporosis, age-related macular degeneration, kidney disease for human use, * excluding pharmaceutical preparations for the treatment and prevention of HIV *
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, April 12, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTokyo 103-8426
JP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 103-8426
JP
Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 103-8426
JP

Trademark Events

Event DateEvent Description
Thursday, December 15, 2016ASSIGNED TO EXAMINER
Thursday, November 24, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, December 7, 2016LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, December 8, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 13, 2016APPLICATION FILING RECEIPT MAILED
Monday, December 19, 2016NON-FINAL ACTION WRITTEN
Tuesday, December 20, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, December 28, 2016REFUSAL PROCESSED BY MPU
Wednesday, December 28, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, January 12, 2017REFUSAL PROCESSED BY IB
Tuesday, February 14, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 28, 2017ASSIGNED TO LIE
Wednesday, March 1, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 1, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 3, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 6, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, May 11, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Thursday, August 17, 2017NEW REPRESENTATIVE AT IB RECEIVED
Thursday, August 17, 2017LIMITATION OF GOODS RECEIVED FROM IB
Sunday, August 20, 2017EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Thursday, August 24, 2017LIMITATION FROM THE IB EXAMINED AND ENTERED
Tuesday, September 26, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, December 26, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, February 22, 2018TEAS SECTION 7 REQUEST RECEIVED
Saturday, January 13, 2018FINAL DISPOSITION PROCESSED
Sunday, January 14, 2018FINAL DISPOSITION NOTICE SENT TO IB
Saturday, February 3, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, April 4, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, April 5, 2018CORRECTION UNDER SECTION 7 - PROCESSED
Wednesday, June 5, 2019POST REGISTRATION ACTION MAILED - SEC. 7
Friday, May 24, 2019TEAS SECTION 7 REQUEST RECEIVED
Tuesday, June 4, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, June 12, 2019TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Friday, June 21, 2019AMENDMENT UNDER SECTION 7 - PROCESSED
Monday, September 26, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, April 12, 2024CANCELLED SECTION 71

Related Keywords

rekipla disease pharmaceutical disorders infection treatment prevention preparations musculoskeletal mood neurological